Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$37.0M | -$56.5M | -$49.2M | -$48.9M | -$43.8M | -$38.6M | -$32.6M | -$23.4M | -$27.5M | -$43.0M |
| Net income | -$36.4M | -$55.7M | -$46.9M | -$46.7M | -$6.00M | -$43.2M | -$41.3M | -$27.0M | -$62.3M | -$15.3M |
| EPS (diluted) | -$2.36 | -$2.72 | -$1.71 | -$1.59 | -$0.20 | -$1.03 | -$0.89 | -$0.56 | -$1.02 | -$0.53 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.9M | -$46.2M | -$41.0M | -$37.3M | -$34.8M | -$36.7M | -$27.0M | -$23.9M | -$25.4M | -$32.8M |
| Capital expenditures | $2.20M | $266K | $355K | $25.0K | $76.0K | $5.00K | $269K | $34.0K | — | $174K |
| Free cash flow | -$30.1M | -$46.5M | -$41.3M | -$37.3M | -$34.9M | -$36.7M | -$27.3M | -$24.0M | — | -$33.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.05M | $45.1M | $39.2M | $5.15M | $16.5M | $63.5M | $13.2M | $12.6M | $8.74M | $4.58M |
| Total assets | $140M | $94.8M | $118M | $83.6M | $85.5M | $109M | $68.2M | $45.6M | $68.9M | $71.1M |
| Total liabilities | $7.35M | $9.94M | $7.90M | $12.5M | $13.4M | $12.3M | $12.1M | $6.87M | $36.3M | $9.91M |
| Shareholders' equity | $133M | $84.8M | $110M | $71.1M | $72.1M | $97.2M | $56.1M | $38.7M | $32.6M | $61.2M |
| Retained earnings | -$67.9M | -$124M | -$170M | -$217M | -$223M | -$266M | -$308M | -$335M | -$397M | -$412M |
| Shares (wtd avg diluted) | 20.9M | 21.0M | 29.3M | 29.3M | 29.5M | 41.9M | 46.6M | 48.0M | 61.0M | 79.7M |
Every figure is extracted from Corvus Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.